Abstract: [Problem to be Solved] Provided is a delivery carrier into the cell having high antioxidant activity, intracellular absorbability, intracellular disintegration property, stability and safety, which have high delivery property of the active ingredient to cell and living tissues. [Solution] The delivery carrier into cells includes a vitamin derivative with co-activation of both autophagy-related genes and protease synthesis genes, a polymer molecule containing stimulatory reactivity, an emulsion stabilizer, an active ingredient, and a lipid, thereby providing a delivery carrier into cells with high delivery properties of the active ingredient to cells and living tissues.

Abstract: A measurement device for a light-emitting device includes a light attenuator, a photometric sphere, and a light detector. The light attenuator includes a first surface and a heat dissipator. A first light that is emitted from the first light-emitting device is incident on the first surface. The first surface is configured to absorb a portion of the first light. The heat dissipator is configured to dissipate heat of the first surface. The photometric sphere has an inner surface to reflect the first light reflected by the first surface. The light detector is configured to receive at least a portion of the first light reflected by the inner surface.

Abstract: A measurement device for a light-emitting device includes a light attenuator, a photometric sphere, and a light detector. The light attenuator includes a first surface and a heat dissipator. A first light that is emitted from the first light-emitting device is incident on the first surface. The first surface is configured to absorb a portion of the first light. The heat dissipator is configured to dissipate heat of the first surface. The photometric sphere has an inner surface to reflect the first light reflected by the first surface. The light detector is configured to receive at least a portion of the first light reflected by the inner surface.

Abstract: A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one kind of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and an organic compound with which the fullerene or derivative has been modified or clathrated. The composition is reduced in side effects, has the high ability to eliminate free radicals in the body, and further has excellent preparation stability.

Abstract: As a technical means of enabling the application of a fullerene and an analogue thereof in various fields relating to biocompatibility to achieve a novel function, in particular as a means of applying the same to a cosmetic product, a formulated skin preparation for external use or the like, an antioxidative composition comprising as an active ingredient at least one kind of a fullerene, a fullerene-containing oxygen derivative and the fullerene and the fullerene-containing oxygen derivative modified with or clathrated in an organic compound is prepared.

Abstract: A dermal agent for preventing or treating acne, comprising an ascorbic acid derivative which liberates in vivo ascorbic acid, and a zinc salt or comprising a zinc salt of the ascorbic acid-2-phosphate, and a composition comprising tretinoin and an ascorbic acid derivative or a salt thereof, relieving in the irritation of tretinoin by using the dermal agent and tretinoin in combination.

Abstract: A document managing system includes a document receiving section for receiving document, a document item database for storing a correspondence between the document data and bill of lading (B/L) data, a B/L creating section for creating B/L data according to the document data and the document item database. The document managing system also includes a letter of credit (L/C) storage for storing L/C data, a document storage for storing the document data and the B/L data, a document data collation database for storing a correspondence between the L/C data and the document data, a negotiation request receiving section for receiving negotiation request data for a document bill to which an identifier of the document data is set, and a document collating section for collating, according to the document collation database, the document data indicated by an identifier set to the negotiation request data with the L/C data.

Abstract: Determined is a correlation value R (=I(t)/I(0)) between an intensity I(0) of monitor light at least at one specific wavelength which is detected before cure of resin RSN and I(t) of the monitor light at the specific wavelength which is thereafter detected, and the cure of the resin RSN is judged to be completed when a temporal change of the correlation value R comes to a stable state. In assembly manufacturing, light-cure resin RSN is interposed between at least two members M1 and M2. After the above described cure end point is detected, application of resin curing light to the resin RSN is stopped, and the assembly is transferred.

Abstract: An object of the present invention is to provide a composition for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens, containing a stable activity-type provitamin; a method for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens by administering the composition; and a method of employing the composition. A composition for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens, contains L-ascorbic acid-2-phosphate and/or &agr;-tocopheryl phosphate as a stable activity antioxidant provitamin.

Abstract: A dermal agent for preventing or treating acne, comprising an ascorbic acid derivative which liberates in vivo ascorbic acid, and a zinc salt or comprising a zinc salt of the ascorbic acid-2-phosphate, and a composition comprising tretinoin and an ascorbic acid derivative or a salt thereof, relieving the irritation of tretinoin by using the dermal agent and tretinoin in combination.

Abstract: An electronic account settlement system includes a preauthorization device provided at a vendor site and having a first receiver to receive first identification information of a user. The preauthorization device is configured to initiate a preauthorization request for a subsequent transaction of a product or service between the user and a vendor of the vendor site. An accounting system is provided at a remote location from the preauthorization device. The accounting system has a database including account information relating to a plurality of users and is configured to receive the preauthorization request and decide whether to grant or reject the preauthorization request using the account information.

Abstract: Immune enhancement compositions for vaccines for virus, bacteria and/or infectious pathogens which contain stable activity-type antioxidant provitamins; a method of enhancing the immunity of vaccines for virus, bacteria and/or infectious pathogens with use of these compositions; and use of the above composition. As the stable activity-type antioxident provitamins, at least one compound selected from among L-ascorbic acid derivatives and &agr;-tocopherly phophates is used.

Abstract: The present invention relates to an agent for preventing and treating skin diseases comprising as an active ingredient an ascorbic acid derivative which is a compound represented by the following formula (1) or a salt thereof and which per se exhibits no anti-oxidation activity but is capable of transforming in vivo into a compound having an anti-oxidation activity; wherein R1 represents a group capable of bonding to the carbon at the 2-position of the ascorbic acid skeleton through an ether or ester bond and transformable in vivo into a hydroxyl group, and R2 to R4 may be the same or different and each represents a hydroxyl group or a group derived therefrom.

Abstract: L-Ascorbic acid 2-phosphate zinc salt and a salt hydrate thereof having excellent solubility and exhibiting good stability even under weakly acidic conditions. Also disclosed is a process of manufacturing L-ascorbic acid 2-phosphate zinc salt by displacing a cation of a salt of an L-ascorbic acid 2-phosphate other than a zinc salt with a zinc cation. Further disclosed is a composition containing L-ascorbic acid 2-phosphate zinc salt or a salt hydrate thereof as an active ingredient.

Abstract: A pharmaceutical preparation comprising at least one L-ascorbic acid derivative and at least one antimalignant tumor agent, wherein said L-ascorbic acid derivative provides, on culturing zooblast for 20 hours in a culture medium containing the L-ascorbic acid derivative in a concentration of 5 &mgr;M, an L-ascorbic acid intracellular cumulative amount equal to or greater than that obtained by culturing the zooblast in a culture medium containing magnesium L-ascorbic acid-2-phosphate in a concentration of 50 &mgr;M. Also disclosed is a method of inhibiting cancer metastasis which comprises administering to a person in need of such treatment a dosage effective amount of the L-ascorbic acid derivative. Also disclosed is a method of treating cancer which comprises administering to a person in need of such treatment a dosage effective amount of the pharmaceutical preparation.

Abstract: An object of the present invention is to provide a composition for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens, containing a stable activity-type provitamin; a method for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens by administering the composition; and a method of employing the composition. A composition for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens, contains L-ascorbic acid-2-phosphate and/or &agr;-tocopheryl phosphate as a stable activity antioxidant provitamin.

Abstract: A preparation for administration to animals, comprising a sparingly soluble L-ascorbic acid-2-phosphoric ester salt having a solubility in water of 10 wt % or less, the solubility being a value obtained by placing 100 g of purified water in a 200 ml-volume beaker, stirring the water while keeping the temperature at 20° C., adding 0.1 g of the L-ascorbic acid-2-phosphoric ester salt every 5 minutes by taking care not to cause gelation, and 30 minutes after the addition of L-ascorbic acid-2-phosphoric ester salt when the undissolved L-ascorbic acid-2-phosphoric ester salt is observed visually in the aqueous solution, determining the amount in weight percentage of L-ascorbic acid-2-phosphoric ester salt added based on water, and a method for feeding animals, using the preparation.